Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Relapsed/refractory acute promyelocytic leukemia with RARA-LBD region mutation was salvaged by venetoclax: A case report.

Medicine - 3 Dec 2021

Li Youli, Yu Jieni, Xu Qinhong, Zhang Kejie

Abstract excerpt

RATIONALE: Acute promyelocytic leukemia (APL) is one of the most curable cancers. However, relapse of the disease is a difficult issue in clinical practice and it remains a great challenge that patients have a poor effect of conventional treatment in the clinic. Therefore, new and more effective therapeutic measures are urgently needed. Herein, we report a case of relapsed and refractory APL harboring a RARA-LBD...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Arsenic Trioxide
Share to Bridged Bicyclo Compounds, Heterocyclic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Promyelocytic, Acute

Share to Proto-Oncogene Proteins c-bcl-2

Share to Recurrence

Share to Salvage Therapy

Share to Sulfonamides

Share to Tretinoin

Source

Open in PubMed Open full text

Identifiers

PMID: 35049232
DOI: 10.1097/MD.0000000000028076
PMCID: PMC9191359

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Relapsed/refractory acute promyelocytic leukemia with RARA-LBD region mutation was salvaged by venetoclax: A case report.PMID 35049232Read ↗

Clinical Response to Venetoclax and Decitabine in Acute Promyelocytic Leukemia With a Novel RARA-THRAP3 Fusion: A Case ReportSemantic proximity Read ↗

Venetoclax overcomes resistance to all‐trans retinoic acid in a variant acute promyelocytic leukemia with TNRC18::RARA fusionSemantic proximity Read ↗

Treatment of STAT5b-RARA positive acute promyelocytic leukemia by Venetoclax combining with homoharringtonine, cytarabine: A case report and literature reviewSemantic proximity Read ↗

Acute Promyelocytic Leukemia: Update on the Mechanisms of Leukemogenesis, Resistance and on Innovative Treatment StrategiesSemantic proximity Read ↗

Acute Promyelocytic Leukemia: Update on the Mechanisms of Leukemogenesis, Resistance and on Innovative Treatment StrategiesSemantic proximity Read ↗

Acute promyelocytic leukemia: from highly fatal to highly curableSemantic proximity Read ↗

Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax.Semantic proximity Read ↗

Venetoclax Resistance in Acute Myeloid LeukemiaSemantic proximity Read ↗

Venetoclax in Combination with Hypomethylating Agents for the Treatment of Treatment-Naive B/Myeloid Mixed-Phenotype Acute Leukemia and Relapsed/Refractory Acute Myeloid Leukemia: A Report of 3 Cases.Semantic proximity Read ↗

Current views on the genetic landscape and management of variant acute promyelocytic leukemiaSemantic proximity Read ↗

Acute promyelocytic leukemia (APL): a review of the literatureSemantic proximity Read ↗

Successful treatment of a B/T MPAL patient by chemo-free treatment with Venetoclax,Azacitidine and BlinatumomabSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.